Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110396 · ClinicalTrials.gov registry record · Phase 3
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00110396: Completed Phase 3 study, sponsored by EMD Serono.
NCT00110396 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 260 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110396, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
Primary Outcome
The NAb positive value was defined as NAb value greater or equal to 20 NU/mL. NAbs were detected using a viral cytopathic assay.
Interventions
- BIOLOGICAL Interferon-beta-1a FBS-free/HSA-free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
What the finished NCT00110396 record still lists
NCT00110396 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (66% lower).
The record links to 0 conditions, and to 1 intervention - of which Interferon-beta-1a FBS-free/HSA-free is the first listed.
NCT00110396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00110396 about?
NCT00110396 is a clinical study titled "Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis". The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
What is the current status of trial NCT00110396?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2005-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00110396?
The interventions under investigation include: Interferon-beta-1a FBS-free/HSA-free (BIOLOGICAL).
Who is sponsoring clinical trial NCT00110396?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00110396's enrollment target sits among peer trials
260 1230th of 2000 higher than 767 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia